CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Han W, Ding P, Xu M, et al. of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003;81(6):609–617. doi:10.1016/s0888-7543(03)00095-8
   PubMed Web of Science ®Google Scholar
• Han W, Lou Y, Tang J, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001;357(Pt1):127–135. doi:10.1042/0264-6021:
   PubMedGoogle Scholar
• Hou X, He S, Zhang D, Yang C, Shi Y, Zhang K. Expression and clinical significance of CMTM6 in nonsmall cell lung cancer. DNA Cell Biol. 2020;1:343. doi:10.1089/dna.2020.5564
   Web of Science ®Google Scholar
• Su Y, Lin Y, Zhang L, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014;105(1):26–34. doi:10.1111/cas.12304
   PubMed Web of Science ®Google Scholar
• Si J, Zhang P, Tian D, et al. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. World J Surg Oncol. 2017;15(1):34. doi:10.1186/s12957-016-1094-z
   PubMed Web of Science ®Google Scholar
• Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018;35:233–243. doi:10.1016/j.ebiom.2018.08.012
   PubMed Web of Science ®Google Scholar
• Zhang S, Pei X, Hu H, et al. Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer. Tumour Biol. 2016;37(5):6217–6225. doi:10.1007/s13277-015-4508-6
   PubMedGoogle Scholar
• Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101–105. doi:10.1038/nature23643
   PubMed Web of Science ®Google Scholar
• Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106–110. doi:10.1038/nature23669
   PubMed Web of Science ®Google Scholar
• Duan HJ, Li XY, Liu C, Deng XL. Chemokine-like factor-like MARVEL transmembrane domain-containing family in autoimmune diseases. Chin Med J. 2020;133(8):951–958. doi:10.1097/CM9.0000000000000747
   PubMed Web of Science ®Google Scholar
• Wu K, Li X, Gu H, Yang Q, Liu Y, Wang L. Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer. Int J Biol Sci. 2019;15(12):2576–2583. doi:10.7150/ijbs.33733
   PubMed Web of Science ®Google Scholar
• Sánchez-Pulido L, Martín-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci. 2002;27(12):599–601. doi:10.1016/s0968-0004(02)02229-6
   PubMed Web of Science ®Google Scholar
• Zhong J, Wang Y, Qiu X, et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol. 2006;39(5):537–545. doi:10.5483/bmbrep.2006.39.5.537
   PubMedGoogle Scholar
• Song HS, Shi S, Lu XZ, et al. Intracellular CMTM2 negatively regulates human immunodeficiency virus type-1 transcription through targeting the transcription factors AP-1 and CREB. Chin Med J. 2010;123(17):2440–2445.
   PubMed Web of Science ®Google Scholar
• Wang L, Wu C, Zheng Y, et al. Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol. 2004;36(8):1492–1501. doi:10.1016/j.biocel.2003.11.017
   PubMed Web of Science ®Google Scholar
• Li H, Li J, Su Y, et al. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene. 2014;33(24):3109–3118. doi:10.1038/onc.2013.282
   PubMed Web of Science ®Google Scholar
• Yang GY, Chen X, Sun YC, Ma CL, Qian G. Chemokine-like factor 1 (CLFK1) is over-expressed in patients with atopic dermatitis. Int J Biol Sci. 2013;9(8):759–765. doi:10.7150/ijbs.6291
   PubMed Web of Science ®Google Scholar
• Kong LL, Wang ZY, Hu JF, Yuan YH, Li H, Chen NH. Inhibition of chemokine-like factor 1 improves blood-brain barrier dysfunction in rats following focal cerebral ischemia. Neurosci Lett. 2016;627:192–198. doi:10.1016/j.neulet.2016.06.003
   PubMed Web of Science ®Google Scholar
• Kong LL, Wang ZY, Hu JF, et al. Inhibition of chemokine-like factor 1 protects against focal cerebral ischemia through the promotion of energy metabolism and anti-apoptotic effect. Neurochem Int. 2014;76:91–98. doi:10.1016/j.neuint.2014.07.004
   PubMed Web of Science ®Google Scholar
• Kong LL, Hu JF, Zhang W, et al. Expression of chemokine-like factor 1 after focal cerebral ischemia in the rat. Neurosci Lett. 2011;505(1):14–18. doi:10.1016/j.neulet.2011.09.031
   PubMed Web of Science ®Google Scholar
• Kong LL, Wang ZY, Han N, et al. Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats. J Neuroinflammation. 2014;11:112. doi:10.1186/1742-2094-11-112
   PubMed Web of Science ®Google Scholar
• Eichel MA, Gargareta VI, D’Este E, et al. CMTM6 expressed on the adaxonal Schwann cell surface restricts axonal diameters in peripheral nerves. Nat Commun. 2020;11(1):4514. doi:10.1038/s41467-020-18172-7
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu TF, Chen XH, et al. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function. Gene. 2017;624:56–65. doi:10.1016/j.gene.2017.04.041
   PubMed Web of Science ®Google Scholar
• Zhang XW, Dun YJ, Tang X, et al. [Expression of chemokine like factor-like myelin and lymphocyte and related proteins for vesicle trafficking and membrane link transmembrane domain-containing protein 2 in rats with varicocele]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(4):579–583. Chinese.
   Google Scholar
• Wu J, Li L, Wu S, Xu B. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value. Cancer Biol Med. 2020;17(3):528–542. doi:10.20892/j.issn.2095-3941.2020.0032
   PubMed Web of Science ®Google Scholar
• Qian C, Xu Z, Chen L, Wang Y, Yao J. Long noncoding RNA LINC01391 restrained gastric cancer aerobic glycolysis and tumorigenesis via targeting miR-12116/CMTM2 axis. J Cancer. 2020;11(21):6264–6276. doi:10.7150/jca.48365
   PubMed Web of Science ®Google Scholar
• Zhang H, Nan X, Li X, et al. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma. Biochem Biophys Res Commun. 2014;447(2):304–310. doi:10.1016/j.bbrc.2014.03.158
   PubMed Web of Science ®Google Scholar
• Shao L, Cui Y, Li H, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007;13(19):5756–5762. doi:10.1158/1078-0432.CCR-06-3082
   PubMed Web of Science ®Google Scholar
• Niu J, Li H, Zhang Y, et al. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia. Leuk Res. 2011;35(6):771–776. doi:10.1016/j.leukres.2010.11.023
   PubMed Web of Science ®Google Scholar
• Jin Y, Qin X, Jia G. SOX10-dependent CMTM7 expression inhibits cell proliferation and tumor growth in gastric carcinoma. Biochem Biophys Res Commun. 2018;507(1–4):91–99. doi:10.1016/j.bbrc.2018.10.172
   PubMed Web of Science ®Google Scholar
• Guan L, Ji D, Liang N, Li S, Sun B. Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5. J Cell Mol Med. 2018;22(7):3434–3441. doi:10.1111/jcmm.13620
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang G, Zhang Y, et al. CMTM1_v17 is a novel potential therapeutic target in breast cancer. Oncol Rep. 2014;32(5):1829–1836. doi:10.3892/or.2014.3429
   PubMed Web of Science ®Google Scholar
• Li M, Luo F, Tian X, Yin S, Zhou L, Zheng S. Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: latest Advances. Front Oncol. 2020;10:595973. doi:10.3389/fonc.2020.595973
   PubMed Web of Science ®Google Scholar
• Liang Z, Xie J, Huang L, et al. Comprehensive analysis of the prognostic value of the chemokine-like factor-like MARVEL transmembrane domain-containing family in gastric cancer. J Gastrointest Oncol. 2021;12(2):388–406. doi:10.21037/jgo-21-78
   PubMed Web of Science ®Google Scholar
• Delic S, Thuy A, Schulze M, et al. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets. Genes Chromosomes Cancer. 2015;54(7):433–443. doi:10.1002/gcc.22255
   PubMed Web of Science ®Google Scholar
• Cao L, Yang C, Zhu B, et al. A novel protein CMTM1-v5 specifically induced human lymphoma cells apoptosis in vitro and in vivo. Exp Cell Res. 2019;385(1):111623. doi:10.1016/j.yexcr.2019.111623
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang S, Tan S, et al. Downregulated CMTM2 Poses Potential Clinical Significance in Hepatocellular Carcinoma. DNA Cell Biol. 2020;39(4):683–689. doi:10.1089/dna.2019.5237
   PubMed Web of Science ®Google Scholar
• Zhang S, Tian R, Bei C, et al. Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:5731–5741. doi:10.2147/OTT.S250370
   PubMed Web of Science ®Google Scholar
• Li W, Zhang S. CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells. Oncol Res. 2017;25(2):285–293. doi:10.3727/096504016X14732523471442
   PubMed Web of Science ®Google Scholar
• Lu M, Huang Y, Sun W, Li P, Li L, Li L. miR-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 2018;52(2):589–598. doi:10.3892/ijo.2017.4222
   PubMed Web of Science ®Google Scholar
• Yuan W, Liu B, Wang X, et al. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer. Cancer Lett. 2017;386:77–86. doi:10.1016/j.canlet.2016.11.015
   PubMed Web of Science ®Google Scholar
• Yuan W, Li T, Mo X, et al. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway. Oncotarget. 2016;7(20):29507–29519. doi:10.18632/oncotarget.8789
   PubMedGoogle Scholar
• Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69(12):5194–5201. doi:10.1158/0008-5472.CAN-08-3694
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ma Z, Li Z, et al. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. J Cancer. 2021;12(19):5797–5806. doi:10.7150/jca.57082
   PubMed Web of Science ®Google Scholar
• Han T, Shu T, Dong S, et al. Chemokine-like factor-like MARVEL transmembrane domain-containing 3 expression is associated with a favorable prognosis in esophageal squamous cell carcinoma. Oncol Lett. 2017;13(5):2982–2988. doi:10.3892/ol.2017.5837
   PubMed Web of Science ®Google Scholar
• Liu W, Li J, Zhang D, et al. Trefoil factor 1 and gastrokine 2 inhibit Helicobacter pylori-induced proliferation and inflammation in gastric cardia and distal carcinogenesis. Oncol Lett. 2020;20(6):318. doi:10.3892/ol.2020.12181
   PubMed Web of Science ®Google Scholar
• Xue L, Ouyang Q, Li J, et al. Different roles for p16(INK) (4a) -Rb pathway and INK4a/ARF methylation between adenocarcinomas of gastric cardia and distal stomach. J Gastroenterol Hepatol. 2014;29(7):1418–1426. doi:10.1111/jgh.12547
   PubMed Web of Science ®Google Scholar
• Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: international Trends in Incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–1255. doi:10.1038/ajg.2017.155
   PubMed Web of Science ®Google Scholar
• Sanikini H, Muller DC, Sophiea M, et al. Anthropometric and reproductive factors and risk of esophageal and gastric cancer by subtype and subsite: results from the European prospective investigation into cancer and nutrition (EPIC) cohort. Int J Cancer. 2020;146(4):929–942. doi:10.1002/ijc.32386
   PubMed Web of Science ®Google Scholar
• Xie J, Yuan Y, Liu Z, et al. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities. Clin Transl Oncol. 2014;16(4):402–409. doi:10.1007/s12094-013-1092-3
   PubMed Web of Science ®Google Scholar
• Hu F, Yuan W, Wang X, et al. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells. Clin Transl Oncol. 2015;17(8):632–639. doi:10.1007/s12094-015-1288-9
   PubMed Web of Science ®Google Scholar
• Hu FZ, Yuan WQ, Wang XL, et al. [Knockdown of CMTM3 promotes migration and invasion of PC3 cell in vitro]. Beijing Da Xue Xue Bao Yi Xue Ban. 2016;48(1):594–597. Chinese.
   Google Scholar
• Zhang H, Zhang J, Nan X, et al. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma. Tumour Biol. 2015;36(10):7849–7858. doi:10.1007/s13277-015-3504-1
   PubMedGoogle Scholar
• Abe M, Yamashita S, Mori Y, et al. High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes. BMC Cancer. 2016;16:350. doi:10.1186/s12885-016-2371-5
   PubMed Web of Science ®Google Scholar
• Yuan W, Wei F, Ouyang H, et al. CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway. Cancer Cell Int. 2021;21(1):510. doi:10.1186/s12935-021-02159-5
   PubMed Web of Science ®Google Scholar
• Bei C, Zhang Y, Wei R, et al. Clinical significance of CMTM4 expression in hepatocellular carcinoma. Onco Targets Ther. 2017;10:5439–5443. doi:10.2147/OTT.S149786
   PubMed Web of Science ®Google Scholar
• Zhou HQ, Li JH, Liu LW, Lou JM, Ren ZG. Increased CMTM4 mRNA expression predicts a poor prognosis in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2020;19(6):596–601. doi:10.1016/j.hbpd.2020.06.004
   PubMed Web of Science ®Google Scholar
• Chui NN, Cheu JW, Yuen VW, et al. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Hepatol Commun. 2021. doi:10.1002/hep4.1682
   PubMed Web of Science ®Google Scholar
• Xue H, Li T, Wang P, et al. CMTM4 inhibits cell proliferation and migration via AKT, ERK1/2, and STAT3 pathway in colorectal cancer. Acta Biochim Biophys Sin. 2019;51(9):915–924. doi:10.1093/abbs/gmz084
   Google Scholar
• Li T, Cheng Y, Wang P, et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2015;34:122. doi:10.1186/s13046-015-0236-4
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhao F, Yang K, et al. An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. J Cell Biochem. 2019;120(8):13330–13341. doi:10.1002/jcb.28607
   PubMed Web of Science ®Google Scholar
• Li H, Liu YT, Chen L, et al. CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma. Mol Carcinog. 2021;60(8):556–566. doi:10.1002/mc.23323
   PubMed Web of Science ®Google Scholar
• Plate M, Li T, Wang Y, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Mol Cells. 2010;29(4):355–361. doi:10.1007/s10059-010-0038-7
   PubMed Web of Science ®Google Scholar
• Xu G, Dang C. CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int. 2017;17:113. doi:10.1186/s12935-017-0485-8
   PubMed Web of Science ®Google Scholar
• Wu J. CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma. Cancer Biomark. 2020;29(1):89–99. doi:10.3233/CBM-191226
   PubMed Web of Science ®Google Scholar
• Zhou J, Lei J, Wang J, et al. Bioinformatics-Based Discovery of CKLF-Like MARVEL Transmembrane Member 5 as a Novel Biomarker for Breast Cancer. Front Cell Dev Biol. 2020;7:361. doi:10.3389/fcell.2019.00361
   PubMed Web of Science ®Google Scholar
• Chen Z, Cui N, Zhao JS, et al. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances. Eur J Histochem. 2021;65(1):3173. doi:10.4081/ejh.2021.3173
   PubMed Web of Science ®Google Scholar
• Yuan Y, Sheng Z, Liu Z, et al. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells. J Cancer. 2020;11(13):3762–3770. doi:10.7150/jca.42314
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yuan Y, Zhang Y, et al. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo. Clin Transl Oncol. 2015;17(6):431–437. doi:10.1007/s12094-014-1253-z
   PubMed Web of Science ®Google Scholar
• Cai B, Xiao Y, Li Y, Zheng S. CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis. Oncol Lett. 2017;14(2):1536–1542. doi:10.3892/ol.2017.6350
   PubMed Web of Science ®Google Scholar
• Shao L, Guo X, Plate M, et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun. 2009;379(4):866–871. doi:10.1016/j.bbrc.2008.12.126
   PubMed Web of Science ®Google Scholar
• Li P, Liu K, Li L, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(7):1248–1255. doi:10.1097/IGC.0b013e3182259c31
   PubMed Web of Science ®Google Scholar
• Guo X, Li T, Wang Y, et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun. 2009;387(1):139–142. doi:10.1016/j.bbrc.2009.06.148
   PubMed Web of Science ®Google Scholar
• Ma Y, Shi JF, Qiu HY, et al. [Pathophysiologic mechanism of CMTM5 low expression in multiple myeloma progression]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(1):58–62. doi:10.3760/cma.j.issn.0253-2727.2019.01.011 Chinese.
   PubMedGoogle Scholar
• Niu JH, Bao L, Zhang Y, et al. [Abnormally lower expression of cmtm5 gene in bone marrow cells from patients with multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18(2):363–367. Chinese.
   PubMedGoogle Scholar
• Liu LL, Zhang SW, Chao X, et al. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(2):417–429. doi:10.1007/s00262-020-02691-9
   PubMed Web of Science ®Google Scholar
• Zhu X, Qi G, Li C, et al. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma. DNA Cell Biol. 2019;38(2):193–197. doi:10.1089/dna.2018.4513
   PubMed Web of Science ®Google Scholar
• Yugawa K, Itoh S, Yoshizumi T, et al. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Hepatol Commun. 2020;5(2):334–348. doi:10.1002/hep4.1643
   PubMed Web of Science ®Google Scholar
• Huang X, Xiang L, Wang B, et al. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells. J Transl Med. 2021;19(1):120. doi:10.1186/s12967-021-02787-5
   PubMed Web of Science ®Google Scholar
• Muranushi R, Araki K, Yokobori T, et al. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci. 2021;112(8):3314–3323. doi:10.1111/cas.15004
   PubMed Web of Science ®Google Scholar
• Li X, Chen L, Gu C, Sun Q, Li J. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ. 2020;8:e9536. doi:10.7717/peerj.9536
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhao S, Wang X. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer. Cancer Cell Int. 2021;21(1):78. doi:10.1186/s12935-020-01734-6
   PubMed Web of Science ®Google Scholar
• Peng QH, Wang CH, Chen HM, et al. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer. 2021;9(2):e001638. doi:10.1136/jitc-2020-001638
   PubMed Web of Science ®Google Scholar
• Wu X, Lan X, Hu W, et al. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunol Immunother. 2021;70(11):3235–3248. doi:10.1007/s00262-021-02931-6
   PubMed Web of Science ®Google Scholar
• Shang X, Li J, Wang H, et al. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma. Int Immunopharmacol. 2020;88:106864. doi:10.1016/j.intimp.2020.106864
   PubMed Web of Science ®Google Scholar
• Zugazagoitia J, Liu Y, Toki M, et al. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;14(12):2084–2096. doi:10.1016/j.jtho.2019.09.014
   PubMed Web of Science ®Google Scholar
• Koh YW, Han JH, Haam S, Jung J, Lee HW. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology. 2019;8(10):e1629261. doi:10.1080/2162402X.2019.1629261
   PubMed Web of Science ®Google Scholar
• Wang H, Gao J, Zhang R, Li M, Peng Z, Wang H. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Int Immunopharmacol. 2020;83:106478. doi:10.1016/j.intimp.2020.106478
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang C, Song A, et al. CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1. Am J Cancer Res. 2020;10(6):1691–1709.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang QC, Li YC, et al. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Cancer Immunol Res. 2020;8(2):179–191. doi:10.1158/2326-6066.CIR-19-0394
   PubMed Web of Science ®Google Scholar
• Zhang S, Yan Q, Wei S, et al. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(2):202–209. doi:10.1016/j.oooo.2021.02.019
   PubMed Web of Science ®Google Scholar
• Mohapatra P, Shriwas O, Mohanty S, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis. JCI Insight. 2021;6(4):e143643. doi:10.1172/jci.insight.143643
   PubMed Web of Science ®Google Scholar
• Pang X, Wang SS, Zhang M, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother. 2021;70(4):1015–1029. doi:10.1007/s00262-020-02741-2
   PubMed Web of Science ®Google Scholar
• Ishihara S, Iwasaki T, Kohashi K, et al. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma. J Cancer Res Clin Oncol. 2021;147(7):2003–2011. doi:10.1007/s00432-021-03616-4
   PubMed Web of Science ®Google Scholar
• Huang ZM, Li PL, Yang P, et al. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer. Kaohsiung J Med Sci. 2019;35(6):332–340. doi:10.1002/kjm2.12058
   PubMed Web of Science ®Google Scholar
• Liu B, Su Y, Li T, et al. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation. Oncotarget. 2015;6(38):41092–41107. doi:10.18632/oncotarget.5732
   PubMedGoogle Scholar
• Liu Q, Su Y, Jiang GC, et al. Change of CMTM7 expression, a potential tumor suppressor, is associated with poor clinical outcome in human non-small cell lung cancer. Chin Med J. 2013;126(16):3006–3012.
   PubMed Web of Science ®Google Scholar
• Zhang W, Mendoza MC, Pei X, et al. Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem. 2012;287(15):11850–11858. doi:10.1074/jbc.M111.258236
   PubMed Web of Science ®Google Scholar
• Yan M, Zhu X, Qiao H, Zhang H, Xie W, Cai J. Downregulated CMTM8 Correlates with Poor Prognosis in Gastric Cancer Patients. DNA Cell Biol. 2021;40(6):791–797. doi:10.1089/dna.2021.0110
   PubMed Web of Science ®Google Scholar
• Gao D, Hu H, Wang Y, et al. CMTM8 inhibits the carcinogenesis and progression of bladder cancer. Oncol Rep. 2015;34(6):2853–2863. doi:10.3892/or.2015.4310
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617. doi:10.1056/NEJMra0901557
   PubMed Web of Science ®Google Scholar
• Hu H, Chen JW, Xu KX, et al. [Expressions of CMTM8 and E-cadherin in primary and metastatic clear cell renal cell carcinoma]. Beijing Da Xue Xue Bao Yi Xue Ban. 2013;45(4):537–541. Chinese.
   PubMedGoogle Scholar
• Hatta M, Nagai H, Okino K, et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res. 2004;30(1):53–58. doi:10.1111/j.1341-8076.2004.00156.x
   PubMed Web of Science ®Google Scholar
• Choi JH, Kim YB, Ahn JM, et al. Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer. Exp Mol Med. 2018;50(4):1–11. doi:10.1038/s12276-017-0009-6
   Web of Science ®Google Scholar
• Huang Y, Li F, Du Y. Effects of CKLFSF8 on expression of EGFR of BGC823 cell. J Zhengzhou Univ. 2006;41:617–619.
   Google Scholar
• Zhao W, Xu Y, Xu J, et al. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially. Int Immunopharmacol. 2015;26(2):314–321. doi:10.1016/j.intimp.2015.04.010
   PubMed Web of Science ®Google Scholar
• Bei C, Tan C, Zhu X, Wang Z, Tan S. Association Between Polymorphisms in CMTM Family Genes and Hepatocellular Carcinoma in Guangxi of China. DNA Cell Biol. 2018;37(8):691–696. doi:10.1089/dna.2018.4274
   PubMed Web of Science ®Google Scholar
• Ma BB, Sung F, Tao Q, et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. 2010;28(2):107–114. doi:10.1007/s10637-009-9219-7
   PubMed Web of Science ®Google Scholar
• Li T, Zhong J, Chen Y, et al. Expression of chemokine-like factor 1 is upregulated during T lymphocyte activation. Life Sci. 2006;79(6):519–524. doi:10.1016/j.lfs.2006.01.042
   PubMed Web of Science ®Google Scholar
• Yafune A, Kawai M, Itahashi M, et al. Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model. Toxicol Lett. 2013;222(3):295–302. doi:10.1016/j.toxlet.2013.08.006
   PubMed Web of Science ®Google Scholar
• Kawai M, Saegusa Y, Kemmochi S, et al. Cytokeratin 8/18 is a useful immunohistochemical marker for hepatocellular proliferative lesions in mice. J Vet Med Sci. 2010;72(3):263–269. doi:10.1292/jvms.09-0329
   PubMed Web of Science ®Google Scholar
• Li M, Guo H, Wang Q, et al. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Cancer Lett. 2020;490:20–30. doi:10.1016/j.canlet
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang C, Ning Z, et al. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Ann Transl Med. 2021;9(1):42. doi:10.21037/atm-20-1013
   PubMed Web of Science ®Google Scholar
• Li J, Chen C, Bi X, et al. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 2017;630:1–7. doi:10.1016/j.gene.2017.07.082
   PubMed Web of Science ®Google Scholar
• Li Z, Xie J, Wu J, et al. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One. 2014;9(2):e88965. doi:10.1371/journal.pone.0088965
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
   PubMed Web of Science ®Google Scholar
• Varadi M, Anyango S, Deshpande M, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50(D1):D439-D444. doi:10.1093/nar/gkab1061
   PubMed Web of Science ®Google Scholar
• Fishilevich S, Nudel R, Rappaport N, et al. Genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017;2017:bax028. doi:10.1093/database/bax028
   PubMed Web of Science ®Google Scholar